V
ATRS

Veritable’s Antares Pharma, Inc. ATRS Stock Holding History

Veritable’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-25,000
Closed -$84K – 842
2018
Q3 		$84K Sell
25,000
-25,000
-50% -$77.2K ﹤0.01% 798
2018
Q2 		$129K Sell
50,000
-50,000
-50% -$124K ﹤0.01% 777
2018
Q1 		$220K Hold
100,000
– – ﹤0.01% 721
2017
Q4 		$199K Hold
100,000
– – ﹤0.01% 769
2017
Q3 		$324K Hold
100,000
– – 0.01% 583
2017
Q2 		$322K Sell
100,000
-9,500
-9% -$26.9K 0.01% 612
2017
Q1 		$311K Buy
109,500
+29,500
+37% +$71K 0.01% 596
2016
Q4 		$186K Buy
+80,000
New +$152K ﹤0.01% 706

Other funds holding ATRS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
MWP
MYCIO Wealth Partners Philadelphia, Pennsylvania $502M AUM 11.65% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Veritable's ATRS Position: Q4 2018 in Review

Veritable sold out of Antares Pharma, Inc. (ATRS) in Q4 2018, closing a stake of 25,000 shares — an estimated $84K sold.

Veritable first reported a position in ATRS in Q4 2016 and held it in 8 quarters. The position peaked at $324K in Q3 2017. 120 funds tracked by Wall St. Rank hold ATRS as of Q4 2018.

  • Veritable reported no remaining Antares Pharma, Inc. position as of Q4 2018 after selling out during the quarter.
  • Veritable sold 25,000 Antares Pharma, Inc. shares in Q4 2018, an estimated $84K.
  • Veritable first reported a position in Antares Pharma, Inc. in Q4 2016 and held it in 8 quarters.
  • Veritable's Antares Pharma, Inc. position peaked at $324K in Q3 2017.
  • 120 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q4 2018.

Based on Veritable's 13F filing for Q4 2018, filed 14 Feb 2019.